A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. (Q44200937)

30 November 2017

title

A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. (English)

1 reference

30 November 2017

1 reference

3

R Thiébaut

1 reference

30 November 2017

11

F Dabis

1 reference

30 November 2017

F Bonnet

1

1 reference

30 November 2017

S Lawson-Ayayi

2

1 reference

30 November 2017

R Ramanampamonjy

4

1 reference

30 November 2017

D Lacoste

5

1 reference

30 November 2017

N Bernard

6

1 reference

30 November 2017

D Malvy

7

1 reference

30 November 2017

M Bonarek

8

1 reference

30 November 2017

F Djossou

9

1 reference

30 November 2017

J Beylot

10

1 reference

30 November 2017

P Morlat

12

1 reference

30 November 2017

French Aquitaine Cohort. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA)

13

1 reference

30 November 2017

language of work or name

English

0 references

publication date

28 October 2002

1 reference

Clinical Infectious Diseases

30 November 2017

published in

1 reference

30 November 2017

volume

35

1 reference

30 November 2017

issue

10

1 reference

30 November 2017

page(s)

1231-1237

1 reference

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

30 November 2017

cites work

1 reference

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

21 January 2018

1 reference

Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy

21 January 2018

1 reference

Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1.

21 January 2018

1 reference

Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study

21 January 2018

1 reference

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

Adverse effects of nevirapine

21 January 2018

1 reference

Severe hepatic failure related to nevirapine treatment

21 January 2018

1 reference

Liver toxicity caused by nevirapine

21 January 2018

1 reference

Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage phi X174 in asymptomatic HIV-1 infected patients

21 January 2018

1 reference

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile

21 January 2018

1 reference

A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.

21 January 2018

1 reference

A Randomized, Double-Blind Trial on the Use of a Triple Combination Including Nevirapine, a Nonnucleoside Reverse Transcriptase HIV Inhibitor, in Antiretroviral-Naive Patients With Advanced Disease

21 January 2018

1 reference

Prednisolone does not prevent the occurrence of nevirapine-induced rashes

21 January 2018

1 reference

Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids

21 January 2018

1 reference

Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers

21 January 2018

1 reference

Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA)

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/343046

1 reference

30 November 2017

1 reference